HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.

AbstractIMPORTANCE OF THE FIELD:
Guidelines recommend five antihypertensive drug classes, but which particular drug to choose is up to the treating physician. We aimed at an in-depth comparison of two frequently used angiotensin receptor blockers to provide evidence for this decision.
AREAS COVERED IN THIS REVIEW:
Pharmacology of irbesartan and losartan, their blood-pressure-lowering efficacy, their tolerability/safety, end-organ protective effects and economic evaluation.
WHAT THE READER WILL GAIN:
Both drugs differ in their oral bioavailability, potential for food interactions, degree of metabolism, dosing interval, time to peak, volume of distribution and terminal half-life. Irbesartan provides a greater and longer-lasting antihypertensive effect and was determined to be cost effective over losartan in Denmark and Sweden. Irbesartan was more effective in preventing deterioration of kidney function in patients with diabetic nephropathy, being cost effective from a German perspective. There is only one end point trial for either drug in patients with left ventricular hypertrophy, heart failure and atrial fibrillation, but no direct comparison.
TAKE HOME MESSAGE:
There is an incremental clinical benefit of irbesartan over losartan in the treatment of hypertension and diabetic nephropathy which can be substantiated by corresponding preclinical study evidence. This has translated into an economic benefit in a number of country-specific evaluations.
AuthorsPeter Bramlage, Christoph Schindler
JournalExpert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 11 Issue 4 Pg. 521-35 (Mar 2010) ISSN: 1744-7666 [Electronic] England
PMID20030566 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antihypertensive Agents
  • Biphenyl Compounds
  • Tetrazoles
  • Angiotensin II
  • Irbesartan
  • Losartan
Topics
  • Administration, Oral
  • Angiotensin II (antagonists & inhibitors)
  • Antihypertensive Agents (economics, pharmacokinetics, therapeutic use)
  • Biological Availability
  • Biphenyl Compounds (economics, pharmacokinetics, therapeutic use)
  • Blood Pressure (drug effects, physiology)
  • Diabetic Nephropathies (complications, drug therapy, physiopathology)
  • Health Care Costs
  • Humans
  • Hypertension (complications, drug therapy, physiopathology)
  • Irbesartan
  • Losartan (economics, pharmacokinetics, therapeutic use)
  • Tetrazoles (economics, pharmacokinetics, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: